PNU-176798 is primarily investigated for its potential therapeutic applications in the field of neuroscience. It has been studied for its role as a selective dopamine D2 receptor partial agonist, which makes it a candidate for treating psychiatric disorders such as schizophrenia and bipolar disorder. By modulating dopamine activity in the brain, it may help alleviate symptoms like hallucinations, delusions, and mood instability. Additionally, its partial agonist properties could offer a balance between activating and blocking dopamine receptors, potentially reducing side effects like extrapyramidal symptoms often associated with antipsychotic medications. Research is ongoing to explore its efficacy and safety in clinical settings.